HI
GBT

HBK Investments’s Global Blood Therapeutics, Inc. GBT Stock Holding History

HBK Investments’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-34,600
Closed -$946K – 1154
2017
Q2 		$946K Buy
+34,600
New +$1.03M 0.01% 585

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

HBK Investments's GBT Position: Q3 2017 in Review

HBK Investments sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2017, closing a stake of 34,600 shares — an estimated $946K sold.

HBK Investments first reported a position in GBT in Q2 2017 and held it in 1 quarter. The position peaked at $946K in Q2 2017. 136 funds tracked by Wall St. Rank hold GBT as of Q3 2017.

  • HBK Investments reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • HBK Investments sold 34,600 Global Blood Therapeutics, Inc. shares in Q3 2017, an estimated $946K.
  • HBK Investments first reported a position in Global Blood Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • HBK Investments's Global Blood Therapeutics, Inc. position peaked at $946K in Q2 2017.
  • 136 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2017.

Based on HBK Investments's 13F filing for Q3 2017, filed 14 Nov 2017.